We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Wanted: Medical Device Volunteers for IMDRF Pilot

Wanted: Medical Device Volunteers for IMDRF Pilot

August 7, 2015

Medical device companies looking to get their products approved in more than one jurisdiction are being sought by the International Medical Device Regulators Forum.

IMDRF, a multinational group of device regulators working to harmonize global standards and regulations, is seeking volunteers for a pilot project to evaluate table of contents structures for premarket applications. The ToC documents are expected to be used by companies when filing medical device submissions to multiple regulators. They define the location for both IMDRF and regional content for all submission types.

Slated to begin this September, the pilot is expected to remain open for 12 months, with an eye on finalizing findings by November 2016.

The pilot’s objectives, according to an IMDRF document, are the following:

  • Develop and validate documentation supporting the use of the IMDRF ToCs, based on industryfeedback;
  • Identify possible industry challenges and develop ways to address them;
  • Provide industry and regulators with the opportunity to use ToCs with real submissions in a controlled setting;
  • Evaluate the proper usage of the ToC headings, including the appropriate placement of documents within the headings and submission of complete and relevant content;
  • Identify additional ToC harmonization opportunities; and
  • Establish and ensure ToC pilot technical guidelines are fit for purpose, and to the extent possible, are harmonized among all of the players.

Australia, Brazil, Canada, China, the EU and the U.S. are participating in the current pilot. A previous ToC pilot used historical submissions for products, but, at the time, there were no guidelines for building a regulated product submission. IMDRF is looking to develop a Health Level Seven Regulated Product Submission exchange standard to serve as the international standard for medical device and human pharmaceutical submissions.

Parties may send an e-mail in English by Aug. 21 to imdrftoc@gmail.com indicating their interest in the program.

Several IMDRF countries are conducting corresponding regional pilots. Brazil’s Agência Nacional de Vigilância Sanitária, for example, is encouraging parties to indicate their interest by copying toc.pilot@anvisa.gov.br in their request to IMDRF.

To view the IMDRF document explaining the pilot, visit www.fdanews.com/081015-imdrf.pdf. — Elizabeth Hollis

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • AstraZeneca

    AstraZeneca Withdraws Imfinzi’s Bladder Cancer Indication

  • CE mark

    Cue Health’s COVID-19 Test Receives CE Mark

  • Sanofi-Regeneron_Logos.png

    Sanofi’s and Regeneron’s Libtayo Wins FDA Approval for NSCLC

  • PerkinElmer logo

    PerkinElmer’s Rapid Point-of-Care COVID-19 Test Cleared in Europe

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing